Fifty-two patients with MDS and AML participated in a phase 2 study that assessed the efficacy and safety of eprenetapopt in combination with AZA in patients with high-risk TP53-mutated MDS and AML [73]. This evidence concerns the gene TP53 and acute myeloid leukemia.